Heart Failure

Kianersi discusses how, although evening chronotype can be associated indirectly with increased CVD risk, this can be mediated via Life’s Essential 8 scores.

Palaniappan explains what steps to take in managing cardiovascular disease risk among a population that does not adhere to the Life’s Essential 8 guidelines.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

Catch up with major FDA decisions, critical conference news, and more.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

Sorajja discusses the results of this groundbreaking trial investigating a new implant for patients with severe mitral annular calcification.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.

Gulati discusses how cardiologists should change their standard care practices to include and educate patients, which will reduce treatment burden and improve adherence.

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

The SGLT2 inhibitor also displayed its efficacy in reducing left ventricular myocardial fibrosis and volume, as well as improving diastolic filling dynamics.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Little discusses 2 recently emerged therapies for TR, spotlighting the benefits and limitations associated with each procedure.